A new analysis indicates that the majority of new cancer treatments authorized by European regulators in the past four years do not provide high clinical benefit. The study reviewed 97 approved indications for 63 distinct cancer therapies. According to the findings, only 31 percent of these indications were rated as offering high clinical benefit.
The research utilized measurement tools from the European Society for Medical Oncology to grade the medications. Of the 63 drugs examined, just nine earned the top grade. Additionally, only 19 of the treatments were considered to have at least one high-benefit indication.
High-benefit approvals are concentrated among a limited group of manufacturers. Five drugmakers accounted for more than half of the 30 high-benefit indications granted between January 2022 and July 2026. Four of these five companies are headquartered in China or Japan.
Researchers suggested this geographic concentration represents a fundamental shift in the innovation ecosystem over the last decade.